Equities research analysts expect Integra Lifesciences Holdings Corp (NASDAQ:IART) to announce $349.68 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Integra Lifesciences’ earnings, with the lowest sales estimate coming in at $348.40 million and the highest estimate coming in at $352.30 million. Integra Lifesciences posted sales of $258.64 million in the same quarter last year, which suggests a positive year over year growth rate of 35.2%. The company is scheduled to issue its next quarterly earnings report on Wednesday, April 25th.
According to Zacks, analysts expect that Integra Lifesciences will report full-year sales of $349.68 million for the current fiscal year, with estimates ranging from $1.48 billion to $1.49 billion. For the next financial year, analysts anticipate that the business will report sales of $1.57 billion per share, with estimates ranging from $1.55 billion to $1.59 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that cover Integra Lifesciences.
Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.08. The business had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The company’s quarterly revenue was up 44.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.52 earnings per share.
Several equities research analysts recently weighed in on IART shares. Zacks Investment Research raised shares of Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, December 26th. Oppenheimer set a $58.00 price target on shares of Integra Lifesciences and gave the company a “buy” rating in a report on Tuesday, December 12th. Cantor Fitzgerald reissued a “neutral” rating and issued a $52.00 price target on shares of Integra Lifesciences in a report on Friday, January 5th. TheStreet raised shares of Integra Lifesciences from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. Finally, Bank of America downgraded shares of Integra Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. Eleven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $54.18.
Integra Lifesciences (NASDAQ:IART) traded down $0.70 during mid-day trading on Wednesday, reaching $56.68. 823,349 shares of the company traded hands, compared to its average volume of 531,527. The firm has a market capitalization of $4,504.00, a P/E ratio of 69.12, a P/E/G ratio of 1.77 and a beta of 0.65. Integra Lifesciences has a 1-year low of $40.51 and a 1-year high of $57.61. The company has a quick ratio of 1.51, a current ratio of 2.36 and a debt-to-equity ratio of 1.85.
In other Integra Lifesciences news, Director Christian S. Schade sold 15,658 shares of the business’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $52.88, for a total transaction of $827,995.04. Following the sale, the director now owns 75,262 shares in the company, valued at approximately $3,979,854.56. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Joseph Vinhais sold 6,800 shares of the business’s stock in a transaction dated Friday, March 9th. The stock was sold at an average price of $54.13, for a total value of $368,084.00. The disclosure for this sale can be found here. Insiders sold a total of 79,765 shares of company stock valued at $4,314,208 over the last three months. 21.50% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of IART. First Trust Advisors LP raised its holdings in Integra Lifesciences by 216.1% during the 3rd quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock worth $2,579,000 after buying an additional 34,925 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in Integra Lifesciences during the 3rd quarter worth about $619,000. Stevens Capital Management LP acquired a new stake in Integra Lifesciences during the 3rd quarter worth about $647,000. Prudential Financial Inc. raised its holdings in Integra Lifesciences by 3.3% during the 3rd quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock worth $5,343,000 after buying an additional 3,340 shares during the period. Finally, Principal Financial Group Inc. raised its holdings in Integra Lifesciences by 3.1% during the 3rd quarter. Principal Financial Group Inc. now owns 489,221 shares of the life sciences company’s stock worth $24,696,000 after buying an additional 14,833 shares during the period. Hedge funds and other institutional investors own 90.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Integra Lifesciences Holdings Corp (IART) Expected to Announce Quarterly Sales of $349.68 Million” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/03/20/integra-lifesciences-holdings-corp-iart-expected-to-announce-quarterly-sales-of-349-68-million.html.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.